Chitosan-based systems for the delivery of vaccine antigens.
about
Emulsified phosphatidylserine, simple and effective peptide carrier for induction of potent epitope-specific T cell responsesNasal vaccine innovation.Multifaceted Applications of Chitosan in Cancer Drug Delivery and Therapy.Biocompatibility of chitosan carriers with application in drug delivery.Chitosan: a promising safe and immune-enhancing adjuvant for intranasal vaccines.Evaluation of TLR agonists as potential mucosal adjuvants for HIV gp140 and tetanus toxoid in mice.Carbohydrate-based immune adjuvants.Vaccination of Sheep with a Methanogen Protein Provides Insight into Levels of Antibody in Saliva Needed to Target Ruminal MethanogensThe effect of antigen encapsulation in chitosan particles on uptake, activation and presentation by antigen presenting cellsChitosan is a surprising negative modulator of cytotoxic CD8+ T cell responses elicited by adenovirus cancer vaccines.Applications of polymeric adjuvants in studying autoimmune responses and vaccination against infectious diseases.Respiratory nanoparticle-based vaccines and challenges associated with animal models and translationGalactosylated chitosan oligosaccharide nanoparticles for hepatocellular carcinoma cell-targeted delivery of adenosine triphosphateChitosan and its salts for mucosal and transmucosal delivery.Bioadhesive delivery systems for mucosal vaccine delivery.Recent developments in buccal and sublingual delivery systems.Chitosan-based delivery systems for mucosal vaccines.Micro and nanoparticle-based delivery systems for vaccine immunotherapy: an immunological and materials perspective.Is There an Optimal Formulation and Delivery Strategy for Subunit Vaccines?Intranasal delivery of nanoparticle-based vaccines.Development and Evaluation of CmeC Subunit Vaccine against Campylobacter jejuni.Formulation of chitosan with the polyepitope HIV-1 protein candidate vaccine efficiently boosts cellular immune responses in mice.Chitosan enhances nanoparticle delivery from the reproductive tract to target draining lymphoid organs.Rationalized design of a mucosal vaccine protects against Mycobacterium tuberculosis challenge in mice.Repeated Treatments with Chitosan in Combination with Antibiotics Completely Eradicate Uropathogenic Escherichia coli From Infected Mouse Urinary Bladders.Biomaterial adjuvant effect is attenuated by anti-inflammatory drug delivery or material selection.Fabrication of chitosan/gallic acid 3D microporous scaffold for tissue engineering applications.Chitosan-based systems for intranasal immunization against foot-and-mouth disease.Cationic CaMKII Inhibiting Nanoparticles Prevent Allergic Asthma.The role of chitosan on oral delivery of peptide-loaded nanoparticle formulation.Chitosan Microsphere Used as an Effective System to Deliver a Linked Antigenic Peptides Vaccine Protect Mice Against Acute and Chronic Toxoplasmosis.Nanoparticle Vaccines Adopting Virus-like Features for Enhanced Immune PotentiationOral vaccination based on DNA-chitosan nanoparticles against Schistosoma mansoni infection
P2860
Q27332152-D9C871D0-F04A-4EFC-BDBB-016B11E23822Q30395810-8AA57C3B-2825-41A7-B774-1061454C7084Q33612179-0D1ECBEA-D4A9-44D0-A2F7-D490F71C9961Q33649839-D60D4089-9EA3-4212-BCD3-B83479EBA4FAQ34033764-0EBF628E-BBD4-4D88-A882-81670A248C47Q34524955-F7F61E67-D2E1-402C-99ED-7B17554EB8F3Q35054845-5CFE9B09-47B3-4B6B-879B-0862F9786487Q36089648-A118EE14-275F-48B2-A5F3-2BC761546655Q36553255-D6F4BD18-A633-4DD5-88F3-1DD0F0067054Q36582241-84C263F6-7E9F-40AF-B895-2F39D9F14673Q36591050-255105EC-66D5-49AF-B47E-2D59194EEAF2Q36598433-4D46B715-5B27-4DA7-914D-E0F556B00E72Q37139087-8E29C9CB-2F47-4962-BBC8-CD6774F487CBQ37564537-CF39A1A7-4A6C-4FAA-A036-C3DF671D9B1DQ37805519-D8849A6F-603F-4B91-A0C7-B9DDB52344A6Q38003422-CE7DAA15-3C50-458D-B353-B34C9BE655CDQ38019583-6CCB058A-5511-4659-8F8E-05F88F3A4D80Q38066148-A197BE88-708E-4505-A5A8-F254A660A948Q38886698-BC2145FC-D313-446C-B0C3-40398CB39D91Q39113247-CBFC4869-26DE-4B0E-B3DF-730D1E0DD935Q39465922-4312379E-2FF3-46F5-98C4-026B1B9E69D8Q40040813-C72B1AEA-C230-4332-B48A-49D1F9DD8A97Q40230960-81CCBB57-0D26-43C0-85A5-9133B6C2097CQ40309267-486CD7F7-B8B9-4CCA-BB58-E83979FC520CQ40359535-E5696FE7-6DF9-4179-B710-1693F5F13C11Q41713004-179EA274-5E65-412A-B54A-1F1F7CEB8BB9Q42816177-E45E0CB1-3EF9-4A1E-AAC6-C285F539EAA2Q44643781-0600B8BB-97A1-4BAC-8F05-3E75FBA4440AQ46373828-68581C9C-D38B-44AF-B436-FDFCA69FCBFBQ47449818-B1AAC1AA-8C5D-4BAC-9F34-EB517910073EQ55224227-D93D8A4C-B637-40BC-BA75-42047D83A544Q56993652-8E5A6DEA-58C4-4E33-986F-1F933E87ADD8Q57556377-DB68ED5D-E49D-4C79-88E7-416D84885280
P2860
Chitosan-based systems for the delivery of vaccine antigens.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Chitosan-based systems for the delivery of vaccine antigens.
@en
Chitosan-based systems for the delivery of vaccine antigens.
@nl
type
label
Chitosan-based systems for the delivery of vaccine antigens.
@en
Chitosan-based systems for the delivery of vaccine antigens.
@nl
prefLabel
Chitosan-based systems for the delivery of vaccine antigens.
@en
Chitosan-based systems for the delivery of vaccine antigens.
@nl
P2093
P2860
P356
P1476
Chitosan-based systems for the delivery of vaccine antigens.
@en
P2093
H Ciğdem Arca
Merve Günbeyaz
Sevda Senel
P2860
P304
P356
10.1586/ERV.09.47
P577
2009-07-01T00:00:00Z